The present invention relates to a targeting-type capsule for drug delivery systems. The present invention addresses the problem of providing a capsule for drug delivery systems by utilizing the reactivity of a thiol with an alkyl halide, wherein the capsule comprises a silole-containing carbosilane dendrimer and a labeling protein containing a target recognition site (e.g., green fluorescent protein), can include a biological polymer or another molecule therein, and can deliver the biological polymer or the like selectively into a target cell.

The present invention relates to a targeting-type capsule for drug delivery systems. The present invention addresses the problem of providing a capsule for drug delivery systems by utilizing the reactivity of a thiol with an alkyl halide, wherein the capsule comprises a silole-containing carbosilane dendrimer and a labeling protein containing a target recognition site (e.g., green fluorescent protein), can include a biological polymer or another molecule therein, and can deliver the biological polymer or the like selectively into a target cell.

A modified T cell includes exogenous polynucleotides that encode components of a therapeutic expression system. A first exogenous polynucleotide encodes a therapeutic polypeptide operably linked to a regulatory region inducible by inducer. A second exogenous polynucleotide encodes polypeptide components of a chemical induced proximity (CIP) complex. A third exogenous polynucleotide that encodes a chimeric antigen receptor that specifically binds to an antigen.

A modified T cell includes exogenous polynucleotides that encode components of a therapeutic expression system. A first exogenous polynucleotide encodes a therapeutic polypeptide operably linked to a regulatory region inducible by inducer. A second exogenous polynucleotide encodes polypeptide components of a chemical induced proximity (CIP) complex. A third exogenous polynucleotide that encodes a chimeric antigen receptor that specifically binds to an antigen.

An antigenic peptide comprises the structure X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-P-X.sub.9-X.sub.10-X.sub.11-X.sub.12 and is derived from amino acids 113-124 of alpha synuclein. Ac-cording to the structure: P is proline; X.sub.1 is L, K, A or S, wherein L is leucine, K is lysine, A is alanine and S is serine; X.sub.2 is E or S, wherein E and S are as defined above; X.sub.3 is D, E, K, N, A or S, wherein N is asparagine, D is aspartic acid and D, E, K, A and S are as defined above; X.sub.4 is M, A, S, L or K, wherein M is methionine and A, S, L and K are as defined above; X.sub.5 is P or A as defined above; X.sub.6 is V, A or S, wherein V is valine and A and S are as defined above; X.sub.7 is D or S as defined above; X.sub.9 is D or A as defined above; X.sub.10 is N, S or A, wherein N, S and A are as defined above; X.sub.11 is E, A or S, wherein E, A and S are as defined above; X.sub.12 is present or not and, if present, is A, K, V, S, or G wherein G is glycine and A, K, V and S are as defined above. The structure comprises at least one mutation compared to the wild type L-E-D-M-P-V-D-P-D-N-E-A sequence. The peptide does not comprise the dipeptide Y-E immediately following X12, wherein Y is tyrosine and E is as defined above. The peptides are conjugated to a suitable carrier and useful in treating synucleinopathies.

An antigenic peptide comprises the structure X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-P-X.sub.9-X.sub.10-X.sub.11-X.sub.12 and is derived from amino acids 113-124 of alpha synuclein. Ac-cording to the structure: P is proline; X.sub.1 is L, K, A or S, wherein L is leucine, K is lysine, A is alanine and S is serine; X.sub.2 is E or S, wherein E and S are as defined above; X.sub.3 is D, E, K, N, A or S, wherein N is asparagine, D is aspartic acid and D, E, K, A and S are as defined above; X.sub.4 is M, A, S, L or K, wherein M is methionine and A, S, L and K are as defined above; X.sub.5 is P or A as defined above; X.sub.6 is V, A or S, wherein V is valine and A and S are as defined above; X.sub.7 is D or S as defined above; X.sub.9 is D or A as defined above; X.sub.10 is N, S or A, wherein N, S and A are as defined above; X.sub.11 is E, A or S, wherein E, A and S are as defined above; X.sub.12 is present or not and, if present, is A, K, V, S, or G wherein G is glycine and A, K, V and S are as defined above. The structure comprises at least one mutation compared to the wild type L-E-D-M-P-V-D-P-D-N-E-A sequence. The peptide does not comprise the dipeptide Y-E immediately following X12, wherein Y is tyrosine and E is as defined above. The peptides are conjugated to a suitable carrier and useful in treating synucleinopathies.

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.